The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Rosuvastatin in Older Patients with Systolic Heart Failure
Open accessAbstract
BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical benefit of adding ezetimibe was consistent across patient subgroups [299,444] and also led to a reduction of total CV events [445], stroke [446], and rehospitalizations [447].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [445]
In the citing paper
“The Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico-Effect of Rosuvastatin in Patients with Chronic Heart Failure (GISSI-HF) trials in patients with symptomatic HF did not demonstrate any benefit on CV mortality and non-fatal MI and stroke, in spite of a marked reduction of LDL-C and hs-CRP.36,39”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [36]
In the citing paper
“In two large RCTs 373,374 there was no benefit on hard endpoints, such as CV mortality and non-fatal MI and stroke, in spite of a decrease in hospitalizations 373,375 and a marked reduction of LDL-C and hs-CRP in patients with mainly systolic heart failure.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [373]
In the citing paper
“Trials of low‐dose anticoagulation, 4 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, 5 as well as statins 2 , 6 in patients with HF have been disappointing to date”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
In the citing paper
“Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease (ASCVD), 1 , 2 as designated by professional society guidelines. 3”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citationThe Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 533
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Inhalation of levomepromazine in severe acute asthma
Pedersen, J. E., Olsen, A., & Banning, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91755-8 · Cited by 390
Cited by
Items 401–500 of 1,000
Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Zarić, B. L., Obradovic, M. M., Trpković, A., Banach, M., Mikhailidis, D. P., & Isenović, E. R. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190903112146 · Cited by 46
Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients
Davis, J. W., & Weller, S. C. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043714 · Cited by 48
Statins and New-Onset Diabetes: A Retrospective Longitudinal Cohort Study
Ma, T., Tien, L., Fang, C.-L., Liou, Y., & Jong, G. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.08.004 · Cited by 45
Non-Atheroprotective Effects of Statins
Beri, A., Sural, N., & Mahajan, S. (2009) · American Journal of Cardiovascular Drugs · doi:10.2165/11315710-000000000-00000 · Cited by 42
Immunomodulator Activity of 3-Hydroxy-3-Methilglutaryl-CoA Inhibitors
Smaldone, C., Brugaletta, S., Pazzano, V., & Liuzzo, G. (2009) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152509789541864 · Cited by 42
Oh, J., Lee, B. S., Lim, G., Lim, H., Lee, C. J., Park, S., Lee, S., Chung, J. H., & Kang, S. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.12.007 · Cited by 41
Optimal Antagonism of the Renin-Angiotensin-Aldosterone System: Do We Need Dual or Triple Therapy?
Werner, C. M., Pöss, J., & Böhm, M. (2010) · Drugs · doi:10.2165/11537910-000000000-00000 · Cited by 51
Self-citationAlternatives to transplantation in the surgical therapy for heart failure
Nicolini, F., & Gherli, T. (2008) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2008.11.003 · Cited by 40
Torabi, A., Rigby, A. S., & Cleland, J. G. F. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.080 · Cited by 41
Self-citationThe Heterogeneity of Heart Failure
Francis, G. S., Cogswell, R. J., & Thenappan, T. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.07.978 · Cited by 44
Inflammation as a therapeutic target in heart failure with preserved ejection fraction
Peh, Z. H., Dihoum, A., Hutton, D. L., Arthur, J. S. C., Rena, G., Khan, F., Lang, C. C., & Mordi, I. R. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1125687 · Cited by 50
Marchioli, R., Levantesi, G., Silletta, M. G., Barlera, S., Bernardinangeli, M., Carbonieri, E., Cosmi, F., Franzosi, M. G., Latini, R., Lucci, D., et al. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.70 · Cited by 40
Statins and oxidative stress in chronic heart failure
Costa, S., Reina‐Couto, M., Albino‐Teixeira, A., & Sousa, T. (2016) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2015.12.016 · Cited by 41
Tini, G., Bertero, E., Signori, A., Sormani, M. P., Maack, C., de Boer, R. A., Canepa, M., & Ameri, P. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016309 · Cited by 43
Telomere length and outcome in heart failure
van der Harst, P., de Boer, R. A., Samani, N. J., Wong, L. S. M., Huzen, J., Codd, V., Hillege, H. L., Voors, A. A., van Gilst, W. H., Jaarsma, T., et al. (2009) · Annals of Medicine · doi:10.3109/07853890903233887 · Cited by 40
“15 25 29 [ 12 48 –5 52 2]”
InfluentialThyroid-Stimulating Hormone and Clinical Outcomes
Moreno, A. C. P., Jhund, P. S., Stott, D. J., Gullestad, L. L., Cleland, J. G. F., van Veldhuisen, D. J., Wikstrand, J., KJEKSHUS, J. K., & McMurray, J. J. V. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2013.07.008 · Cited by 40
Self-citationAra, R., Pandor, A., Stevens, J., Rees, A., & Rafia, R. (2009) · Health Technology Assessment · doi:10.3310/hta13340 · Cited by 54
Wang, J., Wu, G., Wang, Z., Dai, X.-P., & Li, X. (2013) · Heart Lung and Circulation · doi:10.1016/j.hlc.2013.07.012 · Cited by 39
“The included studies evaluated rosuvastatin (n = 2) [16,17], simvastatin (n = 1) [18], atorvastatin (n = 3) [19–21], multiple statins (n = 4) [25,27,29,30] or non-specified statins (n = 5) [22– 24,26,28] vs.”
MethodGómez‐Garré, D., González-Rubio, M. L., Muñoz‐Pacheco, P., Caro‐Vadillo, A., Aragoncillo, P., & Fernández‐Cruz, A. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq101 · Cited by 40
Rosuvastatin: efficacy, safety and clinical effectiveness
Soran, H., & Durrington, P. N. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.12.2145 · Cited by 40
Role of Vitamin D in Uremic Vascular Calcification
Hou, Y., Liu, W.-C., Zheng, C., Zheng, J.-Q., Yen, T., & Lu, K. (2017) · BioMed Research International · doi:10.1155/2017/2803579 · Cited by 39
The year in cardiology 2018: heart failure
Cleland, J. G. F., van Veldhuisen, D. J., & Ponikowski, P. P. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz010 · Cited by 42
Self-citationMoroi, M., Nagayama, D., Hara, F., Saiki, A., Shimizu, K., Takahashi, M., Sato, N., Shiba, T., Sugimoto, H., Fujioka, T., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.01.006 · Cited by 43
Review: The therapeutic role of RAS blockade in chronic heart failure
Werner, C. M., & Böhm, M. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708091777 · Cited by 39
Self-citationThe benefit of statins in non-cardiac vascular surgery patients
Stalenhoef, A. F. H. (2009) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.11.070 · Cited by 40
Al-Gobari, M., Le, H.-H., Fall, M., Gueyffier, F., & Burnand, B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171168 · Cited by 38
Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia
Wierzbicki, A. S., Hardman, T. C., & Viljoen, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679340 · Cited by 39
Gheorghiade, M., Flaherty, J. D., Fonarow, G. C., Desai, R. V., Lee, R., McGiffin, D. C., Love, T. E., Aban, I., Eichhorn, E. J., Bonow, R. O., et al. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.04.092 · Cited by 39
Bielecka-Dabrowa, A. M., Mikhailidis, D. P., Rizzo, M., von Haehling, S., Rysz, J., & Banach, M. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-47 · Cited by 39
Ridker, P. M., Kastelein, J. J. P., Genest, J. J., & Köenig, W. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht022 · Cited by 39
Aeschbacher‐Germann, M., Kaiser, N., Speierer, A., Blum, M. R., Bauer, D. C., Giovane, C. D., Aujesky, D., Gencer, B., Rodondi, N., & Moutzouri, E. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026551 · Cited by 46
Heart failure: What does ejection fraction have to do with it?
Iwano, H., & Little, W. C. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.02.017 · Cited by 39
Guo, W., Zhao, L., Huang, W., Chen, J., Zhong, T., Yan, S., Hu, W., Zeng, F., Peng, C., & Yan, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02210-5 · Cited by 44
Rush, C. J., Campbell, R. T., Jhund, P. S., Connolly, E. C., Preiss, D., Gardner, R. S., Petrie, M. C., & McMurray, J. J. V. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.03.013 · Cited by 44
Self-citationStatin Use and the Risk of Incident Diabetes Mellitus: A Review of the Literature
Colbert, J. D., & Stone, J. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.021 · Cited by 39
Tran, J. N., Kao, T. C., Caglar, T., Stockl, K. M., Spertus, J. A., Lew, H. C., Solow, B. K., & Chan, P. S. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.8.901 · Cited by 35
Cho, A., Arfsten, H., Goliasch, G., Bartko, P. E., Wurm, R., Strunk, G., Hülsmann, M., & Pávó, N. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12625 · Cited by 40
Impact of adherence to statins on chronic heart failure in primary prevention
Perreault, S., Dragomir, A., Blais, L., Bérard, A., Lalonde, L., & White, M. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03269.x · Cited by 37
Blum, A. (2009) · PubMed · Cited by 36
Ballo, P., Balzi, D., Barchielli, A., Turco, L., Franconi, F., & Zuppiroli, A. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1980-2 · Cited by 39
Lipoprotein Disorders and Cardiovascular Disease
Genest, J. J., & Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00047-0 · Cited by 38
Marcinkiewicz-Siemion, M., Ciborowski, M., Ptaszynska-Kopczynska, K., Szpakowicz, A., Lisowska, A., Jasiewicz, M., Waszkiewicz, E., Kretowski, A. J., Musiał, W., & Kamiński, K. A. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.03.027 · Cited by 39
Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review
Mollace, V., Rosano, G. M. C., Anker, S. D., Coats, A. J. S., Seferovic, P. M., Mollace, R., Tavernese, A., Gliozzi, M., Musolino, V., Carresi, C., et al. (2021) · Nutrients · doi:10.3390/nu13010257 · Cited by 37
Yang, X. H., Zhang, B. L., Cheng, Y., Fu, S. K., & Jin, H. M. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.07.018 · Cited by 43
Xie, R., Cui, W., Fan, L., Yang, C., Pei, W., & Lu, J. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.030 · Cited by 36
“Although CORONA [8] showed that rosuvastatin did not reduce mortality rate from any cause in older patients with systolic heart failure, it lowered the number of rehospitalizations for cardiovascular causes.”
BackgroundLipid lowering for prevention of venous thromboembolism: a network meta-analysis
Farmakis, I. T., Christodoulou, K. C., Hobohm, L., Konstantinides, S., & Valerio, L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae361 · Cited by 36
Ciolino, J. D., Zhao, W., Martin, R. H., & Palesch, Y. Y. (2010) · Contemporary Clinical Trials · doi:10.1016/j.cct.2010.11.005 · Cited by 35
Vilahur, G., Casaní, L., Peña, E., Juan‐Babot, O., Mendieta, G., Crespo, J., & Badimón, L. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.06.040 · Cited by 36
“Besides, to date, statins have not appeared to improve outcomes in patients with established/advanced heart failure [43,44].”
BackgroundBlois, J. D., Fagerland, M. W., Grundtvig, M., Semb, A. G., Gullestad, L. L., Westheim, A. S., Hole, T., Atar, D., & Agewall, S. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu010 · Cited by 35
“Contrary to other previous observational studies,5 two recent RCTs6,7 have shown that rosuvastatin 10 mg did not affect the main outcome in patients with HF. Bias selection in the observation studies have been pointed at as the most probable reason to explain this discrepancy.”
BackgroundInfluentialSelf-citationBonsu, K. O., Reidpath, D. D., & Kadirvelu, A. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6636-z · Cited by 37
“However, two recent large RCTs—the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) [17] and Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza cardiaca (GISSI-HF) [18]—both failed to show statistically significant benefits in mortality outcomes compared with placebo, although CO…”
BackgroundResultInfluentialDo structural differences in statins correlate with clinical efficacy?
Arnaboldi, L., & Corsini, A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833b776c · Cited by 38
Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006
Rastam, S., Ali, R. A., Maziak, W., Mzayek, F., Fouad, F. M., O’Flaherty, M., & Capewell, S. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-754 · Cited by 36
Khan, S., Huda, B., Bhurka, F., Patnaik, R., & Banerjee, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178429 · Cited by 63
McMurray, J. J. V., Adamopoulos, S. N., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G. S., Fonseca, C., Sánchez, M. Á. G., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.08.003 · Cited by 56
Self-citationMetabolic Syndrome and Heart Failure—The Risk, Paradox, and Treatment
Gaddam, K. K., Ventura, H. O., & Lavie, C. J. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0179-x · Cited by 42
LDL electronegativity index: a potential novel index for predicting cardiovascular disease
Bobryshev, Ivanova, E. A., & Orekhov, A. N. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s74697 · Cited by 38
Lu, Y., Cheng, Z., Zhao, Y., Chang, X., Chan, C., Bai, Y., & Cheng, N. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.025 · Cited by 44
Tsujimoto, T., & Kajio, H. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.109 · Cited by 34
Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease
Adam, O., & Laufs, U. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5526 · Cited by 36
Zhang, L., Zhang, S., Jiang, H., Sun, A., Zou, Y., & Ge, J. (2010) · Clinical Cardiology · doi:10.1002/clc.20821 · Cited by 34
Hammadah, M., Kalogeropoulos, A. P., Georgiopoulou, V. V., Weber, M. E., Wu, Y., Hazen, S. L., Butler, J., & Tang, W. H. W. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.777 · Cited by 35
Arıkan, İ., Metintaş, S., Kalyoncu, C., & Yıldız, Z. (2009) · PubMed · Cited by 86
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction
Cunningham, J. W., Vaduganathan, M., Claggett, B. L., John, J. E., Desai, A. S., Lewis, E. F., Zile, M. R., Carson, P., Jhund, P. S., Kober, L., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.02.007 · Cited by 33
Self-citationEstler, B., Fröhlich, H., Täger, T., Hund, H., Frey, N., Luft, T., & Frankenstein, L. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133566 · Cited by 39
Zhang, W. B., Du, Q., Li, H., Sun, A., Qiu, Z., Wu, C. N., Zhao, G., Gong, H., Hu, K., Zou, Y., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01536.x · Cited by 37
Kurabayashi, M., Yamazaki, T., & SUBARU Study Group (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e567 · Cited by 33
Statins and diabetes risk: Fact, fiction, and clinical implications
Rocco, M. B. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12091 · Cited by 38
Sudden Cardiac Death in Heart Failure
Klein, L., & Hsia, H. H. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.008 · Cited by 35
Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure
Bielecka-Dabrowa, A. M., Fabiś, J., Mikhailidis, D. P., von Haehling, S., Sahebkar, A., Rysz, J., & Banach, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.003 · Cited by 31
The Underlying Chemistry of Electronegative LDL’s Atherogenicity
Ke, L., Stancel, N., Bair, H., & Chen, C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0428-y · Cited by 35
Inglis, S. C., McMurray, J. J. V., Böhm, M., Schaufelberger, M., van Veldhuisen, D. J., Lindberg, M., Dunselman, P., Hjalmarson, Å. C., KJEKSHUS, J. K., Waagstein, F., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq070 · Cited by 33
Self-citationInflammation in Heart Failure—Future Perspectives
Arvunescu, A. M., Ionescu, R. F., Creţoiu, S. M., Dumitrescu, S. I., Zaharia, O., & Nanea, I. T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247738 · Cited by 46
The good and bad effects of statins on insulin sensitivity and secretion
Muscogiuri, G., Sarno, G., Gastaldelli, A., Savastano, S., Ascione, A., Colao, A., & Orio, F. (2014) · Endocrine Research · doi:10.3109/07435800.2014.952018 · Cited by 38
Ferri, N., Ruscica, M., Lupo, M. G., Vicenzi, M., Sirtori, C. R., & Corsini, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106439 · Cited by 35
Is statin‐induced diabetes clinically relevant? A comprehensive review of the literature
Bell, D. S. H., DiNicolantonio, J. J., & O’Keefe, J. H. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12254 · Cited by 32
Zhang, L., Zhang, S., Jiang, H., Sun, A., Wang, Y., Zou, Y., Ge, J., & Chen, H. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.08.009 · Cited by 32
Selvaraj, S., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Juliano, R. A., Jiao, L., Tardif, J., Ballantyne, C. M., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024999 · Cited by 31
Association of genetically predicted lipid traits and lipid-modifying targets with heart failure
Xiao, J., Ji, J., Zhang, N., Yang, X., Chen, K., Chen, L., & Huang, W. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac290 · Cited by 32
McMurray, J. J. V., Anand, I. S., Díaz, R., Maggioni, A. P., O’Connor, C. M., Pfeffer, M. A., Solomon, S. D., Tendera, M., van Veldhuisen, D. J., Albizem, M. B., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs204 · Cited by 34
Self-citationLee, J., Noh, Y., Shin, S., Lim, H., Park, R. W., Bae, S. K., Oh, E., Kim, G. J., Kim, J. H., & Lee, S. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117150 · Cited by 36
Statins in heart failure—With preserved and reduced ejection fraction. An update
Tousoulis, D., Oikonomou, E. K., Siasos, G., & Stefanadis, C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.001 · Cited by 35
DiNicolantonio, J. J., Lavie, C. J., Serebruany, V. L., & O’Keefe, J. H. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.01.2620 · Cited by 34
Statins and n-3 fatty acid supplementation in heart failure
Fonarow, G. C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61241-6 · Cited by 31
Sunset for Statins after AURORA?
Strippoli, G. F., & Craig, J. C. (2009) · New England Journal of Medicine · doi:10.1056/nejme0901067 · Cited by 31
Inflammation and heart failure: a two-sample Mendelian randomization study
Remmelzwaal, S., van Oort, S., Handoko, M. L., van Empel, V. P. M., Heymans, S. R. B., & Beulens, J. W. J. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001373 · Cited by 34
Dyslipidemia in Patients with Chronic and End-Stage Kidney Disease
Omran, J., Al‐Dadah, A., & Dellsperger, K. C. (2013) · Cardiorenal Medicine · doi:10.1159/000351985 · Cited by 30
Statins and New-Onset Diabetes
Barylski, M., Nikolić, D., Banach, M., Toth, P. P., Montalto, G., & Rizzo, M. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660678 · Cited by 30
“On the other hand, several studies showed that frequently used statins (simvastatin, atorvastatin and rosuvastatin) - have negative effects on glycemic control [4-6,13,24,26,29-32] as well on insulin action and glucose uptake [33-35].”
BackgroundFibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction
Juillerat‐Jeanneret, L., Aubert, J., Mikulic, J., & Golshayan, D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00294 · Cited by 30
Pharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 42
Efficacy of statin therapy in chronic systolic cardiac insufficiency: A meta-analysis
Zhang, S., Zhang, L., Sun, A., Jiang, H., Qian, J., & Ge, J. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.06.003 · Cited by 30
Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction
Teshima, Y., Yufu, K., Akioka, H., Iwao, T., Anan, F., Nakagawa, M., Yonemochi, H., Takahashi, N., Hara, M., & Saikawa, T. (2008) · Journal of Cardiology · doi:10.1016/j.jjcc.2008.08.008 · Cited by 30
Tsutamoto, T., Yamaji, M., Kawahara, C., Nishiyama, K., Fujii, M., Yamamoto, T., & Horie, M. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp144 · Cited by 30
Borger, M. A., Seeburger, J., Walther, T., Borger, F., Rastan, A. J., Doenst, T., & Mohr, F. W. (2010) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2009.12.001 · Cited by 29
Castro, M. R., Simon, G., Cha, S. S., Yawn, B. P., Melton, L. J., & Caraballo, P. J. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-015-3583-0 · Cited by 34
Rossi, A., Inciardi, R. M., Rossi, A., Temporelli, P. L., Lucci, D., Gonzini, L., Marchioli, R., Nicolosi, G. L., & Tavazzi, L. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.03.001 · Cited by 29
Statin associated muscle symptoms: An update and review
Dicken, W., Mehta, A., Karagiannis, A. D., Jain, V., Vavuranakis, M., Sperling, L. S., & Cassimatis, D. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.010 · Cited by 31
The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review
Abohelwa, M., Kopel, J. J., Shurmur, S. W., Ansari, M. M., Awasthi, S., & Awasthi, S. (2023) · Journal of Vascular Diseases · doi:10.3390/jvd2010010 · Cited by 62
Statin Therapy in Patients with Diastolic Heart Failure
Tehrani, F., Morrissey, R. P., Phan, A., Chien, C., & Schwarz, E. R. (2010) · Clinical Cardiology · doi:10.1002/clc.20615 · Cited by 29
Nakagomi, A., Seino, Y., Kohashi, K., Kosugi, M., Endoh, Y., Kusama, Y., Atarashi, H., & Mizuno, K. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1123 · Cited by 29
Drug safety evaluation of rosuvastatin
Toth, P. P., & Dayspring, T. D. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.626764 · Cited by 32
Metadata
- Authors
- Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, Å., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J. J. V., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D. J., Waagstein, F., Wedel, H., & Wikstrand, J.
- Affiliations
- Oslo University Hospital (NO)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-29
- Volume
- 357
- Issue
- 22
- Pages
- 2248-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126452437
- Cited by
- 1,487
- References
- 27
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 41 · 2023: 43 · 2022: 62 · 2021: 46 · 2020: 63 · 2019: 72 · 2018: 53 · 2017: 75 · 2016: 73 · 2015: 89 · 2014: 96 · 2013: 109 · 2012: 96
- FWCI
- 140.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- rosuvastatin, heart failure with reduced ejection fraction, elderly patients, statins, cardiovascular mortality, cardiovascular hospitalization, LDL cholesterol, high-sensitivity C-reactive protein, statin safety, myocardial infarction, stroke
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Pyrimidines, Sulfonamides, Systole, Proportional Hazards Models, Single-Blind Method, Treatment Outcome, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.